Patients who carried a cytochrome P450 (CYP) 2C9 loss-of-function allele did not have an increased risk for thrombotic events when treated with clopidogrel compared with noncarriers.

It is not necessary to test all patients for the CYP2C9 polymorphisms when starting treatment with clopidogrel.